Piper Sandler Maintains Overweight on Supernus Pharmaceuticals, Lowers Price Target to $41
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst David Amsellem has maintained an Overweight rating on Supernus Pharmaceuticals (NASDAQ:SUPN) but lowered the price target from $45 to $41.

February 28, 2024 | 3:40 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Piper Sandler maintains an Overweight rating on Supernus Pharmaceuticals but lowers the price target from $45 to $41.
While the maintenance of an Overweight rating suggests continued confidence in the company's fundamentals, the reduction in the price target could indicate concerns about near-term growth prospects or market conditions. This mixed signal might lead to short-term uncertainty among investors, potentially causing minor fluctuations in the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100